Emergent BioSolutions, one of only three companies with a vaccine for mpox, has agreed to donate 50,000 doses of its shot for use in the current outbreak concentrated in central Africa, but
Pfizer and BioNTech have been among the leaders in the race to bring a combined COVID-19 and influenza vaccine to market, but have stumbled in the final straight.
The only antiviral recognised as an mpox treatment was unable to shorten the time to resolution of lesions in a trial in the Democratic Republic of the Congo (DRC), the epicentre of an outb
The rapid spread of a new variant of mpox – previously known as monkeypox – has prompted the Africa Centers for Disease Control and Prevention (Africa CDC) to declare a public health emerge
Following the COVID-19 pandemic, mRNA-based vaccines have been shown to provide rapid and precise immune responses, however, this technology has much wider applications.
Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.